Granisetron
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Granisetron
- Granisetron: From Chemotherapy-Induced Nausea and Vomiting to Manic Bipolar Affective Disorder
Granisetron: From Chemotherapy-Induced Nausea and Vomiting to Manic Bipolar Affective Disorder
One-Sentence Summary
Granisetron is a selective 5-HT3 receptor antagonist, used internationally for preventing chemotherapy-induced and postoperative nausea and vomiting. The TxGNN model predicts it may be effective for manic bipolar affective disorder, with 0 clinical trials and 0 publications currently supporting this direction — this remains a pure model-generated hypothesis requiring prospective investigation before any clinical consideration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chemotherapy-induced nausea and vomiting (CINV); postoperative nausea and vomiting (no Canadian regulatory record available) |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology and the repurposing rationale embedded in the TxGNN output, granisetron belongs to the selective 5-HT3 (serotonin type 3) receptor antagonist class — the same class as ondansetron and palonosetron. Its established efficacy in preventing nausea and vomiting associated with chemotherapy and surgery is well-recognised internationally, though no Canadian Drug Identification Numbers (DINs) are on record.
The mechanistic rationale for bipolar mania centers on the limbic system: 5-HT3 receptors are expressed in the amygdala and hippocampus, where they modulate the local balance of dopamine and serotonin release. By antagonising these receptors, granisetron could theoretically dampen hyperactive monoaminergic tone that characterises manic episodes. This is not an entirely novel concept — a related drug, ondansetron, has appeared in exploratory studies for mood disorders, lending the hypothesis a degree of class-level biological plausibility.
That said, mechanistic plausibility should not be conflated with demonstrated efficacy. The TxGNN knowledge-graph model identified this link through indirect node associations in a large biological network, not through observed clinical outcomes. The absence of any published trial or case report for granisetron specifically in bipolar mania means this prediction must be treated as a hypothesis-generating signal, not a clinically actionable finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Granisetron currently has no Drug Identification Numbers (DINs) on the Canadian market. No regulatory approvals, brand names, or dosage form records are available in this Evidence Pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Research Question
Rationale: All ten predicted indications — including manic bipolar affective disorder — rest exclusively on TxGNN model output (Evidence Level L5). No supporting clinical trials, observational studies, or published literature were identified in this search. Without any empirical evidence, this prediction cannot advance to a formal repurposing programme at this time.
To proceed, the following is needed:
- Mechanism of action confirmation: Retrieve full MOA data from DrugBank (DB00889) to formally validate whether 5-HT3 antagonism in limbic circuits provides a mechanistically coherent basis for mood stabilisation.
- Canadian safety profile: Obtain the full prescribing information (warnings, contraindications, and drug-drug interactions) from the authoritative source, as all safety fields are currently unavailable.
- Literature sweep for the drug class: Search ondansetron (the same drug class) in bipolar disorder and other predicted indications to assess whether class-level evidence exists that could inform granisetron’s plausibility ranking.
- Regulatory pathway assessment: Granisetron is not marketed in Canada. Any future clinical investigation would require establishing the regulatory pathway (IND/CTA equivalent) before initiating prospective studies.
- Prioritisation review: Of the 10 predicted indications, three were already scored as “Hold” by the internal pipeline (acute contagious conjunctivitis, angioedema, nephrogenic syndrome of inappropriate antidiuresis, cold urticaria) due to weak mechanistic links. Focus resources on the “Research Question” indications with more coherent biological rationale: bipolar mania, Tourette syndrome, allergic urticaria, trichotillomania, and bronchitis.
This report is for research reference only and does not constitute medical advice. All repurposing candidates require prospective clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.